Stock LVTX LAVA THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
2.73 USD +3.41% Intraday chart for LAVA Therapeutics N.V. +0.74% +72.78%
03-20 LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-20 LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on LAVA Therapeutics N.V.

Price target over the last 5 years

History of analyst recommendation changes

9072efa4fa43602f6209d9bf191f2.HNEZKlW7ZzZQRsPBewT8EwggqDKwWtw-R1TPoHhHPTI.dfx2TDThIH4gLJaFEHyrXVwR4UCHI4kOPWP7100Of0FGnXZ1DOs4fyoL9w~189101be9a42abdf9a6531459507a706

Analyst Recommendations on LAVA Therapeutics N.V.

HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating MT
HC Wainwright Starts Lava Therapeutics at Buy With $9 Price Target MT
SVB Securities Adjusts Price Target on Lava Therapeutics to $28 From $25, Keeps Outperform Rating MT
JMP Securities Starts Lava Therapeutics at Market Outperform With $6 Price Target MT
SVB Securities Adjusts LAVA Therapeutics' Price Target to $25 From $23, Keeps Outperform Rating MT
SVB Leerink Adjusts Price Target on Lava Therapeutics to $20 from $24, Keeps Outperform Rating MT
LAVA THERAPEUTICS B : SVB Leerink Adjusts Price Target on LAVA Therapeutics to $24 From $26, Maintains Outperform Rating MT
LAVA THERAPEUTICS B : JP Morgan Starts Lava Therapeutics at Overweight with $22 Price Target MT
LAVA THERAPEUTICS B : Jefferies Starts Lava Therapeutics at Buy with $23 Price Target MT
LAVA THERAPEUTICS B : SVB Leerink Initiates LAVA Therapeutics at Outperform Rating With $26 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.557 EUR
Average target price
6.684 EUR
Spread / Average Target
+161.37%
High Price Target
10.13 EUR
Spread / Highest target
+296.14%
Low Price Target
5.527 EUR
Spread / Lowest Target
+116.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering LAVA Therapeutics N.V.

HC Wainwright
SVB Securities LLC
JMP Securities
SVB Leerink
J.P. Morgan Chase
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LVTX Stock
  4. Consensus LAVA Therapeutics N.V.